Future perspective for potential Helicobacter pylori eradication therapies. (24th May 2018)

• Record Type: Journal Article
• Authors: Debraekeleer, Ayla; Remaut, Han
• Is Part Of: Future microbiology. Volume 13:Number 6(2018)
• Page Start: 671
• Page End: 687
• Publication Date: 2018-05-24
• Subjects: antibacterial -- antibiotic resistance -- antivirulence therapy -- gastric cancer -- Helicobacter pylori -- peptic ulcer; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2017-0115
• Languages: English
• ISSNs: 1746-0913

Abstract

Helicobacter pylori infection of the human stomach causes chronic inflammation and forms a major risk factor for the development of peptic ulcer disease and gastric cancer. Current standard eradication therapies use an acid-suppressing drug and two antibiotics, now frequently supplemented with bismuth. Declining eradication efficiencies, off-target effects of lengthy broad-spectrum antibiotic treatments and the desire of a more systematic eradication in asymptomatic H. pylori carriers to suppress gastric cancer incidence spur a search for an effective vaccine and alternative therapeutic options. Here, we review the current progress in the field, with an emphasis on narrow-spectrum or nonantibiotic therapeutics.